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Introduction
The introduction of drug eluting stents (DES) for the
treatment of coronary heart disease has significantly
reduced in-stent restenosis, however the use of cytostatic
agents causes delayed re-endothelialisation of the target
vessel. Here we describe the drug release profiles for
rapamycin incorporated into a novel acrylic-based
polymer designed to promote vascular re-
endothelialisation. 2 Understanding drug release from
the surface of DES is integral to the stent development
process. It is useful for testing the reliability and
reproducibility of coatings and for providing insight into
mechanisms of drug release. 1
Experimental Methods
A polymer coating, BTL AccelerateTM AT, proprietary to
Biomer Technology Ltd, was applied to glass coverslips
by dip-coating. Varying AT/rapamycin(R) coating
concentration and ATR ratios, see Table 1, were assessed
for release of drug over a period of 28 days (n=6).
Coverslips were immersed in 1.5 ml of release medium,
phosphate buffered saline:ethanol (90:10), and were
transferred to fresh release medium at regular sampling
points, to maintain sink conditions. Initial drug load was
determined by immersing coverslips (n=2) in 1.5 ml of
methanol every 24 hours for 7 days. The amount of
rapamycin in release medium was determined by
ultraviolet spectroscopy. Comparisons were drawn
between all formulations tested using 2-way ANOVA
with Bonferronis post-test. Significance was considered
P<0.05.
Table 1: Formulations of polymer/rapamycin used to
coat glass coverslips used for drug release profile
determination. AT=polymer, R=rapamycin.
clinic such as the TAXUS stent, which was coated with
high and low polymer/drug ratios to yield slow and
medium rate release profiles, respectively4. The
cumulative release of initial drug load, figure 3, indicates
that high AT/R ratio formulations eluted a significantly
lower percentage of drug during the initial 24 hours. This
is comparable to the Cypher DES which released around
80% of drug load after 30 days.3 The total amount of
drug released over the release period could be controlled
by addition of a drug free polymer only top coat
combined with a high AT/R bottom coating, which
reduced the drug amount released (figure 3).
Sample Bottom Coat Top Coat Drug Load (µg)
1 2% AT/R (50:50) None 32
2 2% AT/R (50:50) 2% AT 19
3 2% AT/R (50:50) 2% AT/R (50:50) 39
4 8% AT/R (80:20) None 66
5 8% AT/R (80:20) 8% AT 62
6 8% AT/R (80:20) 8% AT/R (80:20) 149
Results and Discussion
The cumulative amount of drug released over the release
period for all formulations is shown in figure 1 (1 vs 2
p<0.01, all others p<0.001 at 28 days). The release
profiles generated were similar to those for stents used
clinically, such as the ENDEAVOR stent which releases
the majority of its dose within 2 weeks. 3 Coatings with a
high AT/R ratio eluted drug at a significantly slower rate
than the low ratio formulations and this was most
apparent in the initial 24 hours of the release period
(Figure 2).This is in line with stents that been used in the
Figure 1: Cumulative release of rapamycin. Right
panel: focus on 24 hour period.
Figure 2: Cumulative percentage release of rapamycin.  
Right panel: focus on 24 hour period.
Figure 3: Cumulative percentage release of rapamycin
initial load. Right panel: focus on 24 hour period.
Conclusions
This study has demonstrated that rapamycin can be
incorporated and released in clinically relevant
concentrations, from a polymer designed to promote re-
endothelialisation. Future in vivo studies will investigate
the potential of this polymer/drug coating as an advanced
stent coating.
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